---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005357"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:25:11.566489+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aligos reports Q2 net loss $19.9M ($0.47), cash $159.3M, advances HBV/siRNA programs

## Summary
- Net loss $19.9M ($0.47/share) vs $29.8M ($0.79) in Q2 2021.
- Cash & investments $159.3M at June 30, 2022 (down from $205.8M at Dec 31, 2021); funds ops into H1 2024.
- R&D expenses decreased to $16.5M from $24.6M YoY, reflecting STOPS/ASO wind-down.
- Completed enrollment in multiple CAM-2 and NASH Phase 1 cohorts; on track to file CTA for siRNA ALG-125755 in Q3 2022.
- COVID-19 3CL PI ALG-097558 shows only 3-fold EC50 shift against resistant mutant vs >50-fold for nirmatrelvir.

## SEC filing metadata
- accession: 0001171843-22-005357
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/0001171843-22-005357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/f8k_080322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005357
- JSON: https://secwatch.observer/filing/0001171843-22-005357.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.